Influenza vaccination in heart transplant recipients

Fraund, S.; Wagner, Doris; Pethig, Klaus; Drescher, J.; Girgsdies, Otto; Haverich, Axel

doi:10.1016/s1053-2498(98)00013-8

Cited by 58 publications

(41 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fraund et al vaccinated 79 heart recipients with the 1996/ 1997 trivalent vaccine. The vaccination was well tolerated and effective but the antibody levels were lower than healthy controls (37). Pediatric patients after both renal and liver transplantation were protected by influenza vaccination (76), although the percentage of pediatric liver recipients with protective antibody titer 1 month after the vaccination was only 67% in one study (75).…”

Section: Influenza Vaccinementioning

confidence: 88%

Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols

Duchini¹,

Goss²,

et al. 2003

View full text Add to dashboard Cite

Recipients of solid-organ transplantation are at risk of severe infections due to their life-long immunosuppression. Despite emerging evidence that vaccinations are safe and effective among immunosuppressed patients, most vaccines are still underutilized in these patients. The efficacy, safety, and protocols of several vaccines in this patient population are poorly understood. Timing of vaccination appears to be critical because response to vaccinations is decreased in patients with end-stage organ disease and in the first 6 months after transplantation. For these reasons, the primary immunizations should be given before transplantation, as early as possible during the course of disease. Vaccination strategy should include vaccination of household contacts and health care workers at transplant centers unless contraindicated. No conclusive data are available on the use of immunoadjuvants and screening for protective titers. Most vaccines appear to be safe in solid-organ transplantation recipients, but live vaccines should be avoided until further studies are available. The risk of rejection appears minimal. Recommended vaccines include pneumovax, hepatitis A and B, influenza, and tetanus-diphtheria. We outline specific protocols and recommendations in this particular patient population. Specific contraindications exist for other vaccines, such as yellow fever, oral polio vaccine, bacillus Calmette-Guerin, and vaccinia. We conclude that solid-organ recipients will benefit from consistent immunization practices. Further studies are recommended to improve established protocols in this patient population

show abstract

Section: Influenza Vaccinementioning

confidence: 88%

Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols

Duchini¹,

Goss²,

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Low-level histological rejection has been described in heart transplant recipients after influenza vaccination, 83 but other investigators have not confirmed this finding. 67,84 To our knowledge, there are no reported episodes of hepatic allograft rejection after influenza vaccine.…”

Section: Administration Of Influenza Vaccine To Liver Transplant Recimentioning

confidence: 95%

“…Efficacy in immunodepressed individuals is described as adequate in renal and heart transplant recipients by some investigators. 47,67 Adult liver transplant recipients have also been reported to be adequately protected by the vaccine. In the study of Burbach et al, 65 protective postimmunization titers at 21 days for the 3 antigens contained in the vaccine (A/Bayern/07/95, A/Wuhan/359/95, and B/Bejing/ 184/93) were 92%, 92%, and 95% in liver transplant recipients compared with 97%, 100%, and 100% in healthy controls, respectively.…”

Section: Vaccinationmentioning

confidence: 99%

Influenza Infection in Patients Before and After Liver Transplantation

Duchini¹

2000

Liver Transplantation

View full text Add to dashboard Cite

Infection with influenza virus poses specific problems in pediatric and adult liver transplant recipients, both before and after liver transplantation. These include a higher rate of pulmonary and extrapulmonary complications, development of rejection with graft dysfunction, prolonged shedding of influenza virus, and increased drug-resistance. Hepatic decompensation may occur during influenza infection in patients with cirrhosis. Current prophylaxis includes yearly vaccination with trivalent inactivated vaccine. Appropriate diagnosis and prompt treatment of any upper respiratory infections are indicated in these patients. In this review, we describe a case of influenza viral pneumonia in an adult liver transplant recipient, review basic and clinical aspects of influenza infection in this patient population, and discuss current modes of prevention and treatment in detail. (Liver Transpl 2000;6: 531-542.)

show abstract

“…In one study, kidney transplant recipients who were 3-10 years posttransplant had a 93% seroprotection rate to A(H1N1) antigen after vaccination (232). Among persons with kidney or heart transplants, seroresponse rates were similar or slightly reduced compared with healthy persons (232)(233)(234)(235)(236)(237). However, a small study involving participants with liver transplants indicated a reduced immunologic response to influenza vaccinations (238).…”

Section: Immunocompromised Personsmentioning

confidence: 99%